Trial · NCT04847518
Assessment of Efficacy of KAN-JANG® in Mild COVID-19
NCT04847518, Phase 2, Phase 3, Unknown, Swedish Herbal Institute AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Assessment of Efficacy of KAN-JANG® in Mild COVID-19. Trials, record NCT04847518. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04847518
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Assessment of Efficacy of KAN-JANG® in Mild COVID-19
- NCT number
- NCT04847518
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Swedish Herbal Institute AB
- Conditions
- Covid19
- Interventions
- Kan Jang capsules, Placebo capsules
- First posted
- 2021-04-19
- Last updated
- 2021-09-22
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of symptoms of mild COVID-19: number of days before symptoms disappear | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Time (days) from randomization to symptoms disappear |
| Primary | The severity of the COVID-19 total and individual symptoms: headache, loss of smell, gustatory dysfunction, rhinorrhoea, nasal congestions, cough, sore throat, asthenia, myalgia, and fever | Change from baseline during the period of the treatment and follow up (trough 21 days after randomization) | Time (days) from randomization to the relief of total and individual mild COVID symptoms scores. |
| Primary | Duration of infection | from Day 1 to Day 14 after randomisation | Time (days) from randomization to negative SARS-Cov-2 PCR test |
| Primary | Number of participants clinically recovered | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Number of participants (n) without symptoms of mild COVID |
| Secondary | Severity of Respiratory symptoms and quality of life scores | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Wisconsin Upper Respiratory Symptom Survey Questionary Score |
| Secondary | Cognitive performance test | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | d2-test of attention score |
| Secondary | Immune response marker | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | IL-6 concentration in the serum, pg/ml. |
| Secondary | Hypercoagulation marker | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization | Dimer-D, ng/ml |
| Secondary | Inflammatory marker | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | C-reactive protein, mg/L |
| Secondary | Physical activity | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Assessed by Habitual Physical Activity Questionnaire Score |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Cancellation Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04847518
GET https://conductscience.org/api/trials/v1/NCT04847518/registered